Frazier Life Sciences

Frazier Life Sciences is a healthcare investment firm focusing on companies developing novel therapeutics. We have two core funds that enable investments across all stages of therapeutics companies: Venture Funds Our Venture Funds primarily invest in private companies, focusing on company creation (over 30 companies formed since 2005) and Series A & B companies. We form true partnerships with distinctive entrepreneurs to build highly valuable companies and accelerate the advancement of new therapeutic options for patients. Our latest Venture Fund is Frazier Life Sciences XI, a $987 million fund that was raised in 2022. Public Funds Our Public Funds provide capital to small- and mid-cap public biotech companies in financings, including follow-ons, including CMPOs, PIPEs, IPOs, as well as supporting our companies in the open market. We partner with our public portfolio companies as we do with our private portfolio companies. The Public Funds are investing over $1 billion of committed capital.